ImmunoCellular Therapeutics Ltd

Calabasas, CA, United States

ImmunoCellular Therapeutics Ltd

Calabasas, CA, United States
SEARCH FILTERS
Time filter
Source Type

NEW YORK and SAN DIEGO, May 12, 2017 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (Nasdaq:IMUC) in the United States District Court for the Central District of California on behalf of purchasers of ImmunoCellular securities from May 1, 2012 through December 11, 2013, inclusive (the “Class  Period”). Investors who have incurred losses in shares against ImmunoCellular Therapeutics, Ltd. are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com. If you suffered a loss in the shares of ImmunoCellular Therapeutics, Ltd., and would like to assist with the litigation process as a lead plaintiff, you may, no later than June 30, 2017, request that the Court appoint you lead plaintiff of the proposed class. The filed Complaint alleges that that Defendants made false and misleading statements and/or failed to disclose that ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote ImmunoCellular, which led the market to believe that ImmunoCellular’s clinical studies for its product candidate ICT-107 was going well. On April 10, 2017, the Securities and Exchange Commission (SEC) announced enforcement actions against ImmunoCellular, as well as other individuals and entities, for engaging in stock promotion schemes. Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation. If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at www.whafh.com. ## Follow the firm and learn about newly filed cases on Twitter and Facebook. ## Attorney Advertising. Prior results do not guarantee or predict a similar outcome.


IRVINE, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE:IMUC). Investors who purchased or otherwise acquired shares between May 1, 2012 and December 11, 2013, inclusive (the “Class Period”), are encouraged to contact the Firm before the June 30, 2017 lead plaintiff motion deadline. If you purchased ImmunoCellular shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com. There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member. According to the Complaint, during the Class Period, ImmunoCellular issued materially false and/or misleading statements and/or failed to disclose: that the Company retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote the Company; and that the market was led to believe that the Company’s clinical studies for its product candidate ICT-107 were going well and the share price was artificially inflated. When this news was announced, ImmunoCellular’s stock price fell materially, which harmed investors according to the Complaint. On April 10, 2017, the SEC announced enforcement actions against numerous individuals and entities, including ImmunoCellular, that engaged in stock promotion schemes. If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com. This press release may constitute Attorney Advertising in some jurisdictions.


LOS ANGELES, May 08, 2017 (GLOBE NEWSWIRE) -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE MKT:IMUC) concerning possible violations of federal securities laws between May 1, 2012 and December 11, 2013 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the June 30, 2017 lead plaintiff motion deadline. To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com. No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member. According to the Complaint, throughout the Class Period, ImmunoCellular issued materially false and/or misleading statements and/or failed to disclose: that ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote the Company; and that as a result of this scheme, the market was led to believe that the Company’s clinical studies for its product candidate ICT-107 was going well and the share price was artificially inflated. When this news reached the public, the Company’s stock price dropped materially, which harmed investors according to the Complaint. On April 10, 2017, the Securities and Exchange Commission announced enforcement actions against numerous individuals and entities, including ImmunoCellular, which engaged in stock promotion schemes. Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


LOS ANGELES, May 08, 2017 (GLOBE NEWSWIRE) -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE MKT:IMUC) concerning possible violations of federal securities laws between May 1, 2012 and December 11, 2013 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the June 30, 2017 lead plaintiff motion deadline. To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com. No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member. According to the Complaint, throughout the Class Period, ImmunoCellular issued materially false and/or misleading statements and/or failed to disclose: that ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote the Company; and that as a result of this scheme, the market was led to believe that the Company’s clinical studies for its product candidate ICT-107 was going well and the share price was artificially inflated. When this news reached the public, the Company’s stock price dropped materially, which harmed investors according to the Complaint. On April 10, 2017, the Securities and Exchange Commission announced enforcement actions against numerous individuals and entities, including ImmunoCellular, which engaged in stock promotion schemes. Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


News Article | September 13, 2017
Site: www.prnewswire.com

As previously reported by the Company in a Form 8-K filed on June 29, 2017, the Company was previously notified by NYSE MKT that it was not in compliance with the stockholders' equity continued listing standard as set forth in Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the Company Guide, which require stockholders' equity of $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years. In order to maintain its listing, the Company submitted a plan of compliance addressing how it intends to regain compliance and the plan has been accepted by the NYSE MKT. The Company has been granted until December 23, 2018, subject to periodic review by the NYSE MKT for compliance with the initiatives set forth in the plan, to regain compliance. If the Company is not in compliance with the continued listing standards by December 23, 2018, or if it does not make progress consistent with the plan during the plan period, the NYSE MKT staff may initiate delisting proceedings as appropriate. The NYSE MKT notice has no immediate impact on the listing of the Company's common stock, which will continue to trade on the NYSE MKT exchange under the symbol "IMUC," with the added designation of ".BC" to indicate that the Company is not in compliance with the NYSE MKT's listing standards, subject to periodic review by the NYSE MKT. ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular's pipeline includes: a Stem-to-T-Cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells; ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting CD133 found in recurrent glioblastoma; and ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting ovarian cancer. ImmunoCellular recently announced the wind-down of its phase 3 trial of ICT-107 in HLA-A2 patients while it pursues a collaborative arrangement or sale of its ICT-107 program. To learn more about ImmunoCellular, please visit www.imuc.com. This press release contains certain forward-looking statements, including statements regarding ImmunoCellular's intentions and current expectations concerning, among other things, whether ImmunoCellular's ability to timely submit a plan of compliance; ImmunoCellular's ability to regain compliance with the NYSE MKT LLC's listing standards; and ImmunoCellular's ability to achieve its other clinical, operational, strategic and financial goals. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include the risk that the Company will not be able to timely regain compliance with the NYSE MKT LLC's listing standards.  Additional risks and uncertainties are described under the heading "Risk Factors" in ImmunoCellular's most recently filed quarterly report on Form 10-Q for the period ended June 30, 2017. These forward-looking statements speak only as of the date hereof.  ImmunoCellular undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Patent
Immunocellular Therapeutics Ltd. and Cedars Sinai Medical Center | Date: 2014-02-14

Compositions of multipeptide vaccines including tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating ovarian cancers using such vaccines.


Patent
Immunocellular Therapeutics Ltd | Date: 2014-02-14

Compositions of multipeptide vaccines comprising at least seven tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from at least seven tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating gynecological and peritoneal cancers using such vaccines.


Patent
Cedars Sinai Medical Center and ImmunoCellular Therapeutics Ltd. | Date: 2014-02-14

Compositions of multipeptide vaccines including tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating ovarian cancers using such vaccines.


Patent
ImmunoCellular Therapeutics Ltd. | Date: 2014-02-14

Compositions of multipeptide vaccines comprising at least seven tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from at least seven tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating gynecological and peritoneal cancers using such vaccines.


Patent
Immunocellular Therapeutics Ltd. | Date: 2013-01-09

An immunogen includes an isolated peptide that includes the amino sequence of any one of SEQ ID NOs:1-21 with four or fewer amino acid substitutions.

Loading ImmunoCellular Therapeutics Ltd collaborators
Loading ImmunoCellular Therapeutics Ltd collaborators